Evidence map›Paper›PMID 38318835›Full record

ArticleCurrent drug discovery technologies2024

Exploring the Therapeutic Potential of

Sarra Hamdani, Hocine Allali, Salim Bouchentouf

Abstract read
PubMed Publisher
In one paragraph

Article in Current drug discovery technologies, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sarra HamdaniDepartment of Chemistry, Faculty of Sciences, Abou Bekr Belkaïd University, P.O. Box 119, Tlemcen 13000, Algeria.
Hocine AllaliDepartment of Chemistry, Faculty of Sciences, Abou Bekr Belkaïd University, P.O. Box 119, Tlemcen 13000, Algeria.ORCID 0000-0001-9611-7606
Salim BouchentoufLaboratory of Natural and Bioactive Substances (LASNABIO), Department of Chemistry, Faculty of Sciences, Abou Bekr Belkaïd University, P.O. Box 119, Tlemcen 13000, Algeria.ORCID 0000-0002-2725-9798

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is a major contributor to cancer-related deaths worldwide, driving the need for effective anticancer therapies with fewer side effects. The exploration of Ginkgo biloba, a natural source, offers a hopeful avenue for novel treatments targeting key colorectal biomarkers involved in CRC treatment.

objectiveThe aim of this study was to explore the binding affinity of natural molecules derived from

methodsA total of 152 polyphenolic compounds from G. biloba were selected and subjected to molecular docking simulations to evaluate their interactions with CRC-related biomarkers. The docking results were analysed to identify ligands exhibiting strong affinities towards the targeted genes, suggesting potential inhibitory effects.

resultsDocking simulations unveiled the strong binding affinities between selected polyphenolic compounds derived from

conclusionThe study demonstrates the potential of

Indexed as

Biomarkers, TumorColorectal NeoplasmsGinkgo bilobaMolecular Docking SimulationPolyphenolsAntineoplastic Agents, PhytogenicComputer SimulationHumansPlant ExtractsAntineoplastic Agents, PhytogenicBiomarkers, TumorPlant ExtractsPolyphenolscolorectal biomarkersColorectal cancerdocking scoringGinkgo bilobapolyphenolstargeted genes.

Identifiers

PMID38318835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.